Crispr Therapeutics AG (CRSP) Stock Analysis

Crispr Therapeutics AG (CRSP) is a publicly traded company in the HEALTHCARE sector. It trades at $52.02, carries a market capitalization of $5.23B. This page summarizes the public market data, fundamentals, and frequently asked questions for CRSP, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $52.02
• Market Cap: $5.23B
• EPS: $-6.17
• 52-Week High: $78.48
• 52-Week Low: $37.02

Market Sentiment

Crispr Therapeutics AG currently has a Neutral sentiment score of 0.12.

About Crispr Therapeutics AG

Crispr Therapeutics AG (CRSP) is a pioneering gene editing company leveraging its proprietary CRISPR/Cas9 technology to develop breakthrough therapies for serious genetic disorders, such as sickle cell disease and beta-thalassemia. Based in Zug, Switzerland, the company is actively expanding its clinical pipeline and forging strategic collaborations to translate its innovative science into effective treatments. With a robust portfolio and a commitment to improving patient outcomes, Crispr The...

GNG Research Analysis

GNG Research scores Crispr Therapeutics AG (CRSP) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CRSP.

Frequently Asked Questions

Does CRSP pay dividends?

Crispr Therapeutics AG (CRSP) does not currently pay a regular dividend.

What is CRSP's market cap?

Crispr Therapeutics AG (CRSP) has a market capitalization of $5.23B with a current stock price of $52.02.